CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and eliminate cancer cells by binding tumor targets and the CD3 protein on ...
Bispecific T-cell engagers (TCEs) aim to combat cancer by simultaneously binding T cells and tumor cells in order to induce the first to kill the second. This approach has failed to work effectively ...
CD3 T-cell engagers have the potential to be a cornerstone of cancer treatment. They guide the immune system to find and eliminate cancer cells by binding tumor targets and the CD3 protein on ...
Zacks Investment Research on MSN
Here's why you should add JANX stock to your portfolio now
Janux Therapeutics JANX is making steady progress across its oncology and immunotherapy pipeline, led by its three ...
Safety and efficacy of TQB2102, a novel bispecific anti-HER2 antibody–drug conjugate, in patients with advanced solid tumors: Preliminary data from the first-in-human phase 1 trial. [212Pb]VMT-α-NET ...
New and updated clinical data to be presented from over 30 patients across systemic lupus erythematosus (SLE) and rheumatoid ...
Sequencing CAR T-cell therapy versus bispecific antibodies in myeloma increasingly hinges on MRD depth, transplant candidacy, ...
Issued on behalf of GT Biopharma, Inc.After more than $1.7 billion in dealmaking and a string of Phase 1 starts in 2026, prostate, pancreatic, ...
Kali Therapeutics, a clinical-stage biotechnology company pioneering next-generation immune-resetting therapies, announced that preclinical data for KT502, its second therapeutic candidate, has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results